Site maintenance Wednesday, November 13th, 2024. Please note that access to some content and account information will be unavailable on this date.
Skip to main content
Full access
Communications and Updates
Published Online: 1 April 2022

Disclosure of Editors’ Financial Relationships

Publication: American Journal of Psychiatry
The American Journal of Psychiatry requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:
Ned H. Kalin, M.D. (Editor-in-Chief): Dr. Kalin reports serving as a consultant to the Board of Scientific Advisors, Pritzker Neuropsychiatric Disorders Consortium; Skyland Trail National Advisory Board, CME Outfitters, LLC, Corcept Therapeutics Incorporated, and the Institute for Early Adversity Research External Scientific Advisory Board at the University of Texas-Austin.
Elisabeth B. Binder, M.D., Ph.D. (Deputy Editor): Dr. Binder reports no financial relationships with commercial interests.
Kathleen T. Brady, M.D., Ph.D. (Deputy Editor): Dr. Brady reports serving as a consultant to Alkermes Pharmaceuticals, Embera Pharma, Genomind, Indivior Pharmaceuticals, Sage Pharmaceuticals, Skyland Trail Treatment Center.
David A. Lewis, M.D. (Deputy Editor): Dr. Lewis reports currently receiving investigator-initiated research support from Merck.
William M. McDonald, M.D. (Deputy Editor): Dr. McDonald reports receiving compensation as the Chair of the Data and Safety Monitoring Board for an NIA-sponsored multicenter study; serving on the Board of Skyland Trail and 3Keys; serving as a consultant for Sage Therapeutics and Signant Health; and receiving past funding from Cervel Neurotherapeutics, NeoSync, Neuronetics, Soterix, and the Stanley Foundation.
Daniel S. Pine, M.D. (Deputy Editor): Dr. Pine reports no financial relationships with commercial interests.
Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor): Dr. Rodriguez reports in the past 3 years having served as a consultant to Epiodyne and Biohaven Pharmaceuticals and receiving grant support from Biohaven Pharmaceuticals.

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 312
PubMed: 35360914

History

Published online: 1 April 2022
Published in print: April 2022

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share